Albert Jen, MD
Otolaryngology · Flushing, NYNPI 1326093543
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $164,500 of the $171,167 with a category attached, or 96.1%. AbbVie accounts for 98.2% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2022 at $59,777 and has fallen 91.9% since, to $4,865 in 2025. Among otolaryngology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 224 payments — averaging $764.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$168K
- Merz North America, Inc.$3K
- Acclarent, Inc$122
- Galderma Laboratories, L.p.$75
- Alk-abello, Inc$25
- Abbott$5
What the payments were for
- Speaking & faculty fees$164,50096%
- Travel & lodging$2,3761%
- Food & beverage$4,2913%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 202 | $168,093 |
| Merz North America, Inc. | 15 | $2,847 |
| Acclarent, Inc | 1 | $122 |
| Galderma Laboratories, L.p. | 3 | $75 |
| Alk-abello, Inc | 2 | $25 |
| Abbott | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$95,100
- BOTOX COSMETIC$23,000
- KYBELLA$6,500
- RELIEVA SPINPLUS Balloon Sinuplasty System$122
- RELIEVA SCOUT Multi-Sinus Dilation System$122
- TruDi$122
How this compares
$171,167 in reported general payments places this provider in the 95th percentile of 701 otolaryngology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluticasone Propionate | 789 | $8,355 |
| Famotidine | 284 | $2,714 |
| Ofloxacin | 39 | $1,731 |
| Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort | 22 | $1,021 |
| Mupirocin | 74 | $541 |
| CefuroximeCefuroxime Axetil | 28 | $417 |
| Mometasone Furoate | 19 | $355 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 19 | $210 |
| Methylprednisolone | 24 | $199 |
| Prednisone | 17 | $198 |
| Omeprazole | 19 | $63 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Flushing
- Robert KellmanSyracuse$2.5M
- Roheen RaithathaNew York$830K
- Nora PerkinsAlbany$300K
- Moshe EphratNew Hyde Park$250K
- Gavin SetzenAlbany$243K
- Habibullah JamalRye Brook$179K
- Dennis KrausNew York$159K
- Nitin BhatiaWhite Plains$120K
- Sveta KarelskyRochester$101K
- Anthony DelsignoreNew York$89K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.